NCT06830629Phase 2Recruiting

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Study sponsor: Maze Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09Estimated
Enrollment · participants74Estimated
Source updated2026-07-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 18 participants

Before: 56 participants (planned). After: 74 participants (planned).

Check registry source